O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma

Journal of Neuro-Oncology

Volumn 114, Issue 1, 2013, Pages 135-140

  Jiang, Xiaoyin ^a   Reardon, David A ^b   Desjardins, Annick ^a   Vredenburgh, James J ^c   Quinn, Jennifer A ^d   Austin, Alan D ^a   Herndon II, James E ^a   McLendon, Roger E ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Chemotherapy; Immunohistochemistry; MGMT; Primary central nervous system lymphoma; Temozolomide

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOMYCIN; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENT CANCER; RETROSPECTIVE STUDY; CENTRAL NERVOUS SYSTEM TUMOR; DRUG RESISTANCE; LONGITUDINAL STUDY; LYMPHOMA; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; VERY ELDERLY; ANALOGS AND DERIVATIVES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RETROSPECTIVE STUDIES;

EID: 84881168288     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1162-y     Document Type: Article

References (34)

1. Kadan-Lottick NS, Skluzacek MC, Gurney JG (2002) Decreasing incidence rates of primary central nervous system lymphoma. Cancer 95(1):193-202
2. Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24(8):1281-1288. doi: 10.1200/jco.2005.04.8819
3. Harder H, Holtel H, Bromberg JEC, Poortmans P, Haaxma-Reiche H, Kluin-Nelemans HC, Menten J, van den Bent MJ (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62(4):544-547
4. Mohile NA, Abrey LE (2007) Primary central nervous system lymphoma. Semin Radiat Oncol 17(3):223-229
5. Bessell EM, Hoang-Xuan K, Ferreri AJM, Reni M (2007) Primary central nervous system lymphoma - biological aspects and controversies in management. Eur J Cancer 43(7):1141-1152
6. DeAngelis LM, Iwamoto FM (2006) An update on therapy of primary central nervous system lymphoma. Hematology 1:311-316. doi: 10.1182/asheducation-2006.1. 311
7. Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA (2007) Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 48(9):1712-1720
8. Ferreri AJM, Abrey LE, Blay J-Y, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage J, Batchelor T (2002) Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15. J Clin Oncol 21(12):2407-2414. doi: 10.1200/jco.2003.01.135
9. Gerstner E, Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticancer Ther 7(5):689-700. doi: 10.1586/14737140.7.5.689
10. Panageas Katherine S, EBELB-PLMDLEA (2007) Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 110(6):1338-1344
11. Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glasmacher A, Schmidt-Wolf IG, Klockgether T, Schlegel U (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64(7):1184-1188. doi: 10.1212/01.wnl.0000156350. 49336.e2
12. Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694-703. doi: 10.1634/theoncologist.11-6-694
13. Abrey LE, Correa DD (2005) Treatment-Related Neurotoxicity. Hematol Oncol Clin N Am 19(4):729-738
14. Herrlinger U, Kuker W, Platten M, Dichgans J, Weller M (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58(10):1573-1574
15. Lerro KA, Lacy J (2002) Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 59(2):165-168
16. Makino K, Nakamura H, Kudo M, Takeshima H, Kuratsu J (2007) Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma-case report. Neurol Med Chir (Tokyo) 47(5):229-232
17. Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96(6):864-867. doi: 10.1038/sj.bjc.6603660
18. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63(5):901-903
19. Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJM (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40(11):1682-1688
20. Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang-Xuan K (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85(2):207-211
21. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12):3851-3857
22. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003. doi: 10.1056/NEJMoa043331
23. Kurzwelly D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G, Weller M, Herrlinger U (2010) Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 97(3):389-392. doi: 10.1007/s11060-009-0032-0
24. Makino K, Nakamura H, Hide T-i, Kuratsu J-i (2012) Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol 106(1):155-160. doi: 10.1007/s11060-011-0652-z
25. Quinn JRD, Rich J, et al. (2003) Phase II treatment of adults with newly diagnosed, progressive or recurrent primary central nervous system lymphoma with temodar. Paper presented at the ASCO, Chicago, Ill
26. 6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 78(5):643-644
27. Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101(1):139-145. doi: 10.1002/cncr.20339
28. 6- methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma. Int J Hematol 83(4):341-347
29. Chu LC, CGESAGJGH (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119(10):2487-2491
30. Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, Bernasconi B, Proserpio I, Pinotti G, Tibiletti MG, Furlan D, Capella C (2009) MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. J Clin Pathol 62(8):715-723. doi: 10.1136/jcp.2009.064741
31. 6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118(17):4201-4211. doi: 10.1002/cncr.27392
32. 6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment. J Neuro Oncol 107:147. doi: 10.1007/s11060-011-0721-3
33. Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034-5043. doi: 10.1200/jco.2005.13.524
34. Mutter N, Stupp R (2006) Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6(8):1187-1204